- Home
- IKNA vs BEAT Comparison
IKNA vs BEAT Comparison
Compare IKNA & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- BEAT
- Stock Information
- Founded
- IKNA 2016
- BEAT 2015
- Country
- IKNA United States
- BEAT United States
- Employees
- IKNA N/A
- BEAT N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- IKNA Health Care
- BEAT Technology
- Exchange
- IKNA Nasdaq
- BEAT Nasdaq
- Market Cap
- IKNA 61.8M
- BEAT 51.1M
- IPO Year
- IKNA 2021
- BEAT 2021
- Fundamental
- Price
- IKNA $1.35
- BEAT $1.35
- Analyst Decision
- IKNA Strong Buy
- BEAT Buy
- Analyst Count
- IKNA 1
- BEAT 1
- Target Price
- IKNA $4.00
- BEAT $8.00
- AVG Volume (30 Days)
- IKNA 79.7K
- BEAT 175.9K
- Earning Date
- IKNA 08-07-2025
- BEAT 08-13-2025
- Dividend Yield
- IKNA N/A
- BEAT N/A
- EPS Growth
- IKNA N/A
- BEAT N/A
- EPS
- IKNA N/A
- BEAT N/A
- Revenue
- IKNA N/A
- BEAT N/A
- Revenue This Year
- IKNA N/A
- BEAT N/A
- Revenue Next Year
- IKNA N/A
- BEAT N/A
- P/E Ratio
- IKNA N/A
- BEAT N/A
- Revenue Growth
- IKNA N/A
- BEAT N/A
- 52 Week Low
- IKNA $0.97
- BEAT $1.21
- 52 Week High
- IKNA $1.94
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- IKNA 53.36
- BEAT 37.47
- Support Level
- IKNA $1.31
- BEAT $1.49
- Resistance Level
- IKNA $1.38
- BEAT $1.62
- Average True Range (ATR)
- IKNA 0.06
- BEAT 0.11
- MACD
- IKNA -0.01
- BEAT -0.02
- Stochastic Oscillator
- IKNA 15.79
- BEAT 7.44
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.